Amneal Pharmaceuticals, Inc. (AMRX)
17.89
+0.21
(+1.19%)
USD |
NASDAQ |
Sep 02, 10:41
Amneal Pharmaceuticals Research and Development Expense (Annual) : 186.18M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 186.18M |
| December 31, 2024 | 190.71M |
| December 31, 2023 | 163.95M |
| December 31, 2022 | 195.69M |
| December 31, 2021 | 201.85M |
| December 31, 2020 | 179.93M |
| December 31, 2019 | 188.05M |
| December 31, 2018 | 194.19M |
| December 31, 2017 | 171.42M |
| December 31, 2016 | 80.47M |
| December 31, 2015 | 76.98M |
| December 31, 2014 | 79.11M |
| December 31, 2013 | 68.05M |
| December 31, 2012 | 81.32M |
| Date | Value |
|---|---|
| December 31, 2011 | 82.70M |
| December 31, 2010 | 86.22M |
| December 31, 2009 | 63.27M |
| December 31, 2008 | 59.24M |
| December 31, 2007 | 39.99M |
| December 31, 2006 | 29.64M |
| December 31, 2005 | 26.10M |
| December 31, 2003 | 16.94M |
| December 31, 2002 | 15.55M |
| December 31, 2001 | 10.97M |
| December 31, 2000 | 11.10M |
| December 31, 1999 | 6.479M |
| December 31, 1998 | 2.229M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Liquidia Corp. | 38.45M |
| Eli Lilly & Co. | 13.34B |
| Viatris, Inc. | 952.50M |
| Pfizer Inc. | 10.25B |
| Indivior Pharmaceuticals, Inc. | 80.00M |